Back to homepage

Tag "dapagliflozin"

Effectiveness and safety of dapagliflozin in real-life patients: data from the DAPA-RWE Spanish multicentre study

Authors: Cristóbal Morales, Juan Francisco Merino-Torres, Paloma Moreno-Moreno, María Lainez, Iñigo Tejado, Alfredo Yoldi, Sonsoles Gutiérrez Medina, Alfonso Soto, Manuel A Botana, Virginia Bellido, Irene Caballero

This study evaluates dapagliflozin in
patients with type 2 diabetes in clinical practice in Spain.


DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure

Authors: Edgardo Kaplinsky MD

This review describes the results of the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) trial and the recently published Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction (DEFINE-HF) trial. In addition, the thought-to-be mechanisms of action of SGLT2 inhibitors beyond their known glucose-lowering effects.


Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of anti-diabetic agents

Authors: Eva M Vivian

Although several treatment options are available to reduce hyperglycemia, only about half of individuals with diagnosed diabetes mellitus (DM) achieve recommended glycemic targets. New agents that reduce blood glucose concentrations by novel mechanisms and have acceptable safety profiles are needed to improve glycemic control and reduce complications. This article reviews the evidence from clinical trials and suggests that SGLT2 inhibitors are a promising new treatment option for T2DM.